| Date | Title | | | 05/10/13 | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences| Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (Marketwired) -- 05/10/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in May. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 8:30 a.m. Eastern Time.
Deutsche Bank's 38th Ann... |
|  | | 05/09/13 | Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments| Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing Activities Continue to Progress for Eteplirsen and Additional Duchenne Muscular Dystrophy Drug Candidates; Strong Cash Balance of $175 Million at Quarter-End
CAMBRIDGE, MA -- (Marketwired) -- 05/09/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three mont... |
| | | 05/07/13 | Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus| CAMBRIDGE, MA -- (Marketwired) -- 05/07/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has initiated dosing in a Phase 1 multiple ascending dose (MAD) clinical trial of AVI-7288, the Company's lead drug candidate for the treatment of Marburg virus infection. The Phase I MAD study is designed to characterize the safety, tolerability and pharmacokinetics of AVI-7288 after repeat dosing in healthy adult volunteers. The in... |
| | | 04/26/13 | Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013| CAMBRIDGE, MA -- (Marketwired) -- 04/26/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ Global Market opens on Thursday, May 9, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update.
The conference call may be acc... |
| | | 04/18/13 | Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference| Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (Marketwired) -- 04/18/13 --
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Needham & Company Annual Healthcare Conference in New York, NY on Tuesday, April 30, 2013 at 4:20 p.m. Eastern Time. Chris Garabedian, Sarepta's president and CEO, will be the presenter.
The presentation will be webcast live under the investor relatio... |
| | | 04/15/13 | Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes| Eteplirsen Manufacturing and Clinical Activities Continue as Planned
CAMBRIDGE, MA -- (Marketwired) -- 04/15/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding a potential application for accelerated approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). The FDA has requested that Sarepta provide additional information from the existing eteplirsen dataset to inform a decis... |
| | | 04/11/13 | Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy| Deal Enables Development of New Exon-Skipping Drug Candidates in DMD
CAMBRIDGE, MA and PERTH, AUSTRALIA -- (Marketwired) -- 04/11/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and the University of Western Australia (UWA) today announced that they have entered into an exclusive, worldwide licensing agreement for intellectual property rights to support the development of exon-skipping drug candidates for the treatment of Duchenne muscular dystrophy (DMD). The agreement grants Sarepta rights to... |
| | | 04/05/13 | Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy| Data to Be Presented at the Muscular Dystrophy Association Scientific Conference
CAMBRIDGE, MA -- (Marketwired) -- 04/05/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute ... |
| | | 03/07/13 | Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments| Upcoming Meetings With FDA Will Determine Fastest Path to Pursue Eteplirsen Approval; Additional Drugs for Duchenne Muscular Dystrophy (DMD) Continue to Progress Through Preclinical Development; 2013 Financial Guidance of $18-24 Million in Revenues; $85-115 Million in Operating Loss; Cash Balance of $187 Million at Year-End 2012
CAMBRIDGE, MA -- (MARKETWIRE) -- 03/07/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial resul... |
| | | 03/04/13 | Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates| CAMBRIDGE, MA -- (MARKETWIRE) -- 03/04/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced positive results from a non-human primate study of AVI-7288, the Company's lead drug candidate for the treatment of Marburg virus infection. The data showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in treated subjects, similar to efficacy observed in previous studies that evaluated the drug when... |
| | | 02/21/13 | Sarepta Therapeutics to Present at Cowen & Company 33rd Annual Healthcare Conference| Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (MARKETWIRE) -- 02/21/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Cowen 33rd Annual Healthcare Conference in Boston, MA on March 4 at 2:50pm EST. Chris Garabedian, Sarepta's President and CEO, will be presenting a company overview.
The presentation will be webcast live under the events section of Sarepta Therapeutics' webs... |
| | | 02/20/13 | Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013| CAMBRIDGE, MA -- (MARKETWIRE) -- 02/20/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report fourth quarter and full-year 2012 financial results before the NASDAQ Global Market opens on Thursday, March 7, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate upda... |
| | | 02/04/13 | Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference| Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (MARKETWIRE) -- 02/04/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Leerink Swann Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at 2:00 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarep... |
| | | 01/30/13 | Statement From Sarepta Therapeutics on Stock Volatility| CAMBRIDGE, MA -- (MARKETWIRE) -- 01/30/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today issued the following statement from Chris Garabedian, President and Chief Executive Officer, to address volatility in the Company's stock price resulting from anonymous comments on a social media site that were later deleted.
"As a growing company, we may be subject to market rumors through social media and other anonymous sources. While we do not comment on ... |
| |
|
